Volume 14, Number 3—March 2008
Research
Mycobacterium ulcerans Disease, Peru
Table 1
Patient no. | Geographic origin | Age, y/sex | Patient delay, mo | Localized pain | No. of lesions | Sites | Size of main lesion, cm | Treatment |
---|---|---|---|---|---|---|---|---|
1 | Marañón | 18/M | 8 | Positive | 2 | Left knee | 7 × 6 | Lost to follow-up, no treatment |
2 | Huallaga | 22/F | 1 | Positive | 1 | Left thigh | 2 × 3 | Lost to follow-up, no treatment |
3 | Iquitos | 54/M | 2 | Positive | 2 (right knee earlier, larger) | Both knees | 6 × 7 | Antituberculous drugs and herbal medicines |
4 | Iquitos | 58/F | 8 | Positive | 5 (in a single group) | Left gluteal region | 12 × 16 (sum of all 5) | Anti-Leishmania and herbal medicines |
5 | Tumbes | 46/F | 8 | Positive | 2 (1 lesion was a scar) | Left foot | 5 × 6 | Lost to follow-up, no treatment |
6 | Iquitos | 21/F | 3 | Positive | 1 | Right thigh | 5 × 5 | Antituberculous drugs (regimen 1) and surgery |
7 | Tumbes | 34/F | 2 | Positive | 4 | Right thigh and leg | 6 × 8 | WHO BU antibiotics and surgery |
8 | Tumbes | 45/M | 1 | Positive | 2 | Right middle finger | 8 × 2 | Antituberculous drugs (regimen 1) and surgery |
*WHO, World Health Organization; BU, Buruli ulcer.
Page created: July 07, 2010
Page updated: July 07, 2010
Page reviewed: July 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.